Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Fig. 1

CD58 was highly correlated with poor prognosis by analyzing different databases. a CD58 mRNA expression in liver tumor tissues and normal liver tissues. b, c The TIMER (b) and OncoLnc databases (c) showed high CD58 expression was a poor prognostic indicator for HCC patients. d, e GEPIA (d) and Kaplan–Meier (e) database analysis revealed the relationship of CD58 with OS and disease-free survival in HCC

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us